Non-parametric inference of adverse events under informative censoring.
In long-term treatments or in treatments associated with frequent severe adverse events (AEs) such as those for oncology, it is important to know the probability of occurrence of AEs over time and their severity. However, some patients discontinue treatment and drop out of the clinical trial. Assumption that the drop-outs are non-informative is not always true and are not validated by data. We propose a method of applying competing risk analysis by defining events of 'occurrence of AE' and 'drop-out prior to AE'. We focus on one AE at a time. We distinguish obvious non-informative censoring from other censorings that may not be non-informative. Therefore, our approach does not need an independent assumption for drop-outs. The cumulative incidence function estimator (CIFE) for the AE by severity can be obtained by treating the degree of severity as a competing risk within the AE. We also propose a non-parametric estimator of CIF for sequential occurrence of the same AE by forming a subset of subjects with prior occurrence(s) of the same AE and by applying Wang and Wells' estimator. We give a very simple formulation of the cumulative joint incidence function estimator (CJIFE) for subjects who drop out of the clinical trial after having suffered from the AE at least one time. We evaluate the performance of Pepe's variance estimator for CJIFE with small samples by simulations. We find that it works well with a sample size more than 100. A useful graphical presentation for CIFEs and CJIFE is shown.
Nishikawa
Masako
M
Department of Technology Assessment and Biostatistics, National Institute of Public Health, 3-6, Minami 2 chome, Wako, Saitama-Ken, Japan. mnishikawa@niph.go.jp
Tango
Toshiro
T
Ogawa
Makiko
M
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000379:methods*; D003198:Computer Simulation; D003627:Data Interpretation, Statistical; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010352:Patient Dropouts; D018570:Risk Assessment / Q000379:methods*
D000970:Antineoplastic Agents